Edition:
India

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

23.14USD
13 Dec 2017
Change (% chg)

$-0.40 (-1.70%)
Prev Close
$23.54
Open
$23.53
Day's High
$23.53
Day's Low
$22.95
Volume
1,247
Avg. Vol
6,529
52-wk High
$28.99
52-wk Low
$15.31

Select another date:

Tue, Nov 14 2017

BRIEF-Albireo posts Q3 loss per share $0.73‍​

* Albireo Pharma Inc - ‍decision on potential approval of elobixibat in Japan expected in first half of 2018​

BRIEF-Albireo Pharma to present final results of phase 2 study of A4250 in children with cholestatic liver disease

* Final results of Albireo’s phase 2 study of A4250 in children with cholestatic liver disease presented at the liver meeting 2017

BRIEF-Albireo Pharma files for mixed shelf of up to $125 million‍​

* Albireo Pharma Inc files for mixed shelf of up to $125 million - SEC filing‍​ ‍​ Source text for Eikon: (http://bit.ly/2i8yKC7) Further company coverage:

BRIEF-Albireo elects Roger Jeffs to board of directors

* Albireo Pharma Inc - ‍Jeffs replaces Denise Scots-Knight, who is departing from board​ Source text for Eikon: Further company coverage:

BRIEF-EMA paediatric committee agrees to Albireo's A4250 pediatric investigation plan

* EMA's paediatric committee agrees to Albireo’s a4250 pediatric investigation plan

BRIEF-Albireo Pharma Q2 loss per share $0.86

* Albireo Pharma Inc - qtrly net loss per share diluted $0.86

BRIEF-Albireo Pharma files non-timely 10-K‍​

* Albireo Pharma - unable to file 10-Q quarter ended June 30, 2017 in time due to unexpected delay in preparation of unaudited interim financial statements

Select another date: